Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Enfortumab“
Suchtreffer
Begriffe & Kennungen
Enfortumab vedotin
Eintrag öffnenKeytruda · 4.8 · Pembrolizumab in combination with enfortumab vedotin (see section 4.2) When pembrolizumab is administered in c
Eintrag öffnenKeytruda · 4.8 · Pembrolizumab in combination with enfortumab vedotin (see section 4.2) When pembrolizumab is administered in c
Eintrag öffnenKeytruda · 4.8 · The safety of intravenous pembrolizumab in combination with enfortumab vedotin has been evaluated among 167 pa
Eintrag öffnenKeytruda · 4.8 · The safety of intravenous pembrolizumab in combination with enfortumab vedotin has been evaluated among 564 pa
Eintrag öffnenKeytruda · 4.8 · The safety of pembrolizumab in combination with enfortumab vedotin has been evaluated among 167 patients with
Eintrag öffnenKeytruda · 4.8 · The safety of pembrolizumab in combination with enfortumab vedotin has been evaluated among 564 patients with
Eintrag öffnenPadcev · 4.5 · Based on physiologically-based pharmacokinetic (PBPK) modeling, concomitant use of enfortumab vedotin with ket
Eintrag öffnenPadcev · 4.5 · Effects of other medicinal products on enfortumab vedotin
Eintrag öffnenPadcev · 4.5 · Formal drug-drug interaction studies with enfortumab vedotin have not been conducted. Concomitant administrati
Eintrag öffnenPadcev · 4.8 · 10 Enfortumab vedotin as monotherapy
Eintrag öffnenPadcev · 4.8 · A total of 159 patients were tested for immunogenicity against enfortumab vedotin following enfortumab vedotin
Eintrag öffnenPadcev · 4.8 · A total of 490 patients were tested for immunogenicity against enfortumab vedotin following enfortumab vedotin
Eintrag öffnenPadcev · 4.8 · A total of 697 patients were tested for immunogenicity to enfortumab vedotin 1.25 mg/kg as monotherapy; 16 pat
Eintrag öffnenPadcev · 4.8 · Adverse reactions leading to dose interruption of enfortumab vedotin occurred in 59% of patients. The most com
Eintrag öffnenPadcev · 4.8 · Adverse reactions leading to dose reduction of enfortumab vedotin occurred in 31% of patients. The most common
Eintrag öffnenPadcev · 4.8 · Adverse reactions observed during clinical studies of enfortumab vedotin as monotherapy or in combination with
Eintrag öffnenPadcev · 4.8 · Enfortumab vedotin in combination with pembrolizumab
Eintrag öffnenPadcev · 4.8 · Enfortumab vedotin in combination with pembrolizumab has been studied in 359 patients <65 years and 775 patien
Eintrag öffnenPadcev · 4.8 · In clinical studies of enfortumab vedotin as monotherapy, 30% of patients experienced dry eye during treatment
Eintrag öffnen